Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.1%

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s share price fell 5.1% during mid-day trading on Thursday . The stock traded as low as $13.80 and last traded at $13.89. 43,224 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 320,841 shares. The stock had previously closed at $14.63.

Analyst Ratings Changes

CNTA has been the topic of a number of research analyst reports. Morgan Stanley raised their price objective on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, June 21st. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th.

Centessa Pharmaceuticals Price Performance

The firm has a market capitalization of $1.47 billion, a P/E ratio of -9.78 and a beta of 1.40. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The business’s fifty day moving average is $10.90 and its 200 day moving average is $10.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, analysts forecast that Centessa Pharmaceuticals plc will post -1.61 EPS for the current year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 4,169 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total transaction of $51,362.08. Following the completion of the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at $10,197,941.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now owns 827,755 shares of the company’s stock, valued at $10,197,941.60. The disclosure for this sale can be found here. Insiders have sold a total of 16,873 shares of company stock valued at $206,000 in the last three months. 11.59% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. Quarry LP acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth $48,000. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter worth $90,000. Fred Alger Management LLC bought a new position in Centessa Pharmaceuticals during the second quarter valued at about $99,000. EntryPoint Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter worth about $109,000. Finally, Trexquant Investment LP bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth about $114,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.